The Technical AnalystExchange: EURONEXT Industry: Biotechnology
Genfit SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.29% €3.48
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 172.76 mill |
| EPS: | -0.580 |
| P/E: | -5.99 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 49.71 mill |
| Avg Daily Volume: | 0.0990 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.99 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.99 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 3.40 - 3.56 ( +/- 2.39%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €3.48 (0.29% ) |
| Volume | 0.123 mill |
| Avg. Vol. | 0.0990 mill |
| % of Avg. Vol | 124.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GNFT.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GNFT.PA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.